Company Description
GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States.
Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression.
The company also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders.
The company was founded in 2018 and is based in Dublin, Ireland.
| Country | Ireland |
| Founded | 2018 |
| IPO Date | Jun 25, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 50 |
| CEO | Velichka Valcheva |
Contact Details
Address: Joshua Dawson House, Dawson Street Dublin, D02 RY95 Ireland | |
| Phone | 353 1 437 8334 |
| Website | ghres.com |
Stock Details
| Ticker Symbol | GHRS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001855129 |
| CUSIP Number | G3855L106 |
| ISIN Number | IE000GID8VI0 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Velichka Valcheva M.D., M.Sc. | Chief Executive Officer |
| Florian Schonharting M.Sc. (Econ) | Co-Founder and Non-Executive Chairman of the Board |
| Magnus Halle | Co-Founder and MD of Ireland |
| Julie Ryan F.C.A. | Vice President of Finance |
| Aaron Cameron M.B.A. | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 7, 2025 | EFFECT | Notice of Effectiveness |
| Mar 3, 2025 | UPLOAD | Filing |
| Feb 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2025 | F-3 | Filing |
| Feb 27, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Feb 27, 2025 | 6-K | Report of foreign issuer |
| Feb 12, 2025 | SCHEDULE 13G/A | Filing |
| Feb 10, 2025 | SCHEDULE 13G/A | Filing |
| Feb 10, 2025 | SCHEDULE 13G/A | Filing |
| Feb 6, 2025 | 6-K | Report of foreign issuer |